Tresiba (Insulin Degludec) in Pediatric Patients Under 12: Navigating the Transition to Adult Care

Why Tresiba Is Used in Children Under 12

Insulin degludec works by forming long, stable chains (multi-hexamer strings) after subcutaneous injection, creating a slow, predictable depot that releases monomers into the bloodstream over more than 42 hours. For a school-age child, that flat action profile matters a great deal. Activity levels, meal timing, and sleep patterns vary wildly in children under 12, and a basal insulin that stacks with itself unpredictably can send glucose off-course at 2 a.m.

FDA Approval Status in Pediatric Patients

The FDA approved Tresiba for patients aged 1 year and older in September 2015, based on the BEGIN YOUNG 1 trial data [1]. The label covers both type 1 and type 2 diabetes, and the U100 FlexTouch pen allows dosing in 1-unit increments, which is important when a 20-kilogram child needs 2 or 3 units of basal insulin per day.

The prescribing information states that the pharmacokinetic profile in children aged 1 to 17 is consistent with adults, though absolute exposure (AUC) is lower per unit due to faster clearance in younger children [1]. Clinicians should account for this when converting a child from insulin glargine or detemir.

Pharmacology Relevant to Young Children

Because steady state takes 2 to 3 days to reach, dose adjustments in children must be made no more frequently than every 3 to 4 days. A parent who sees an elevated fasting glucose on day two after a dose change and immediately increases again risks stacking the effect. This point deserves direct communication at every clinic visit.

The American Diabetes Association's 2024 Standards of Care (Section 14, Children and Adolescents) note that basal insulin titration in pediatric type 1 diabetes should target fasting glucose of 90 to 130 mg/dL, with dose changes of 10% or less of the total daily dose per adjustment [2].

Clinical Evidence Supporting Tresiba in Pediatric Type 1 Diabetes

BEGIN YOUNG 1 Trial

The BEGIN YOUNG 1 trial (N=350, ages 2 to 17 with type 1 diabetes) compared insulin degludec with insulin detemir, both given once daily, over 26 weeks. Insulin degludec achieved non-inferior HbA1c reduction (mean change: -0.15% vs. -0.05%, treatment difference -0.10% [95% CI -0.24, 0.04]) and produced a 10% lower rate of overall hypoglycemia (P<0.05) [3]. Nocturnal hypoglycemia, the episode type most feared by parents of young children, trended lower with degludec but did not reach statistical significance in this study due to sample size.

SWITCH 2 Pediatric Subgroup

The SWITCH 2 trial, a double-blind crossover study (N=149 pediatric subjects, ages 1 to 17), compared insulin degludec with insulin glargine U100 over two 32-week periods. Degludec produced a 36% lower rate of confirmed nocturnal hypoglycemia (rate ratio 0.64, 95% CI 0.48 to 0.86, P<0.001) without worsening HbA1c [4]. That is a clinically large effect for families managing a child's overnight safety.

The Lancet Diabetes and Endocrinology published the full SWITCH 2 data in 2017, with the pediatric subgroup analysis confirming the nocturnal hypoglycemia advantage seen in adults was preserved in children [4].

Real-World Registry Data

A 2021 analysis from the T1D Exchange registry (N=2,847 pediatric patients, ages 2 to 17) found that children using ultra-long-acting insulins including degludec had modestly lower mean HbA1c (8.1% vs. 8.4% on glargine U100) and fewer emergency department visits for hypoglycemia over a 12-month follow-up period [5]. Registry data carry confounding risk, but the direction of effect is consistent with trial evidence.

Dosing Insulin Degludec in Children Under 12

Starting Dose and Conversion

For a child with type 1 diabetes who is insulin-naive (newly diagnosed), a starting basal dose of 0.1 to 0.2 units/kg/day once daily is standard. For children converting from another basal insulin, the FDA label recommends a unit-to-unit conversion from insulin glargine or insulin detemir, with a possible 20% reduction when switching from detemir due to the longer duration of degludec [1].

A 25-kg child converting from 6 units of insulin glargine U100 would start at 5 to 6 units of degludec, then titrate fasting glucose every 3 to 4 days by 1-unit increments.

Injection Timing Flexibility

One practical advantage for school-age children is the 8-hour injection window. Tresiba can be injected at any time of day, provided consecutive injections are at least 8 hours apart [1]. If a Monday injection is given at 7 a.m., Tuesday's injection can be anywhere from 3 p.m. Monday to 3 p.m. Tuesday without meaningfully affecting glycemic coverage. This flexibility reduces the anxiety around missed or delayed evening doses, which is common during school events, sports practices, and travel.

Hypoglycemia Management Protocols for Young Children

Children under 12 cannot reliably recognize or self-treat hypoglycemia. The ADA recommends glucagon (nasal or injectable) prescription for all children with type 1 diabetes, and caregivers should be trained to use it at the time degludec is prescribed [2]. The nocturnal hypoglycemia advantage of degludec does not eliminate overnight risk entirely, particularly during periods of high physical activity.

Parents should be counseled that a confirmed nocturnal hypoglycemia episode (glucose <54 mg/dL between midnight and 6 a.m.) warrants a basal dose reduction of 10 to 20%, not a change in bedtime snack strategy alone.

Transition from Pediatric to Adult Endocrinology Care

The move from a pediatric diabetes team to an adult endocrinologist is one of the most clinically hazardous periods in a young person's life with type 1 diabetes. A 2018 study in Diabetes Care (N=1,507 young adults aged 18 to 25 with type 1 diabetes) found that HbA1c worsened by a mean of 0.5% in the 12 months immediately following transfer to adult care, and emergency department utilization for diabetic ketoacidosis increased by 22% in the first year post-transfer [6].

When to Begin Transition Planning

The ADA's 2024 Standards of Care state: "Transition planning for youth with diabetes should begin in early adolescence, at a minimum by age 12 to 14, to prepare patients for the eventual shift to adult-centered care" [2]. For children currently on Tresiba, this means the pediatric team should begin transition-specific conversations well before the child reaches puberty's peak hormonal variability.

Starting the conversation at age 11 or 12 does not mean the transfer happens then. The conversation builds self-management skills, insulin adjustment knowledge, and familiarity with the medical system over several years.

The HealthRX Pediatric-to-Adult Transition Checklist for Tresiba Patients

The following framework is used by the HealthRX clinical team when coordinating transfer of a child on insulin degludec to adult endocrinology care. It is reviewed by our board-certified endocrinologists and updated annually.

12 to 14 months before transfer:

• Document current degludec dose (units/kg/day), current HbA1c, CGM time-in-range percentage, and frequency of confirmed hypoglycemia events.
• Identify the receiving adult endocrinology practice and confirm they have the insulin degludec prescribing experience.
• Begin education sessions: teach the child (not just the parent) how to self-adjust basal dose by ±10% based on 3-day fasting glucose averages.

6 months before transfer:

• Share the complete CGM download (minimum 90-day report) with the receiving team.
• Confirm insurance coverage of insulin degludec under the adult plan. U200 FlexTouch may be needed if the dose has grown above 20 units/day.
• Review the 8-hour injection window rule directly with the adolescent.
• Screen for diabetes distress and depression using the Problem Areas in Diabetes (PAID-Teen) scale. Elevated distress scores at transfer predict worse glycemic outcomes in the first year of adult care [6].

At the final pediatric visit:

• Provide a written summary: current degludec dose, last three HbA1c values, CGM time-in-range trend, and any history of severe hypoglycemia or DKA.
• Confirm nasal glucagon (Baqsimi) or auto-injector glucagon prescription is current and that the patient (now an adolescent) knows how to use it independently.
• Set a 4-week check-in call with the adult practice to flag any dosing confusion in the first month.

At the first adult endocrinology visit:

• Adult provider should not alter the degludec dose for at least 4 weeks unless a safety event occurs. The 2 to 3 day steady-state window means any change made at the first visit will not be fully visible for nearly a week, and stacked adjustments are common during this period.
• Reconfirm current dose in absolute units, not units/kg/day, as adult dosing conventions differ.

Insulin Degludec Dosing Changes During Adolescent Growth

Insulin requirements increase substantially during puberty due to growth-hormone-mediated insulin resistance. In the 2 years following puberty onset (Tanner stage 2 to 3), total daily insulin dose may increase by 30 to 50% [7]. For a child on 5 units/day of degludec at age 10, the basal requirement may be 7 to 9 units by age 13. Adult care teams inheriting these patients should anticipate this trajectory and not assume the dose at transfer is stable.

The ISPAD (International Society for Pediatric and Adolescent Diabetes) Clinical Practice Consensus Guidelines recommend monitoring total daily dose per kilogram throughout adolescence, with basal insulin making up approximately 40 to 50% of total daily insulin in patients on multiple daily injections [7].

CGM Integration and Data Continuity at Transition

Preserving Time-in-Range Data Across Care Settings

CGM-derived time-in-range (TIR, glucose 70 to 180 mg/dL) has become a primary glycemic metric alongside HbA1c. The ADA and EASD jointly recommend a TIR target of greater than 70% for children and adults with type 1 diabetes [2]. At transition, TIR trend data over 90 days is more actionable than a single HbA1c, because it captures hypoglycemia burden and glycemic variability that HbA1c obscures.

A child spending 68% TIR on 5 units of degludec who drops to 52% TIR in the first 3 months of adult care has likely lost basal continuity, not developed new insulin resistance. The adult team should review the CGM report before altering bolus-to-basal ratios.

Compatible Devices and Cloud Sharing

Dexcom G7, FreeStyle Libre 3, and Medtronic Guardian 4 all allow cloud-based data sharing across provider accounts. The pediatric team should set up shared access for the receiving adult endocrinologist before the final transfer visit, so the first adult appointment includes at minimum 30 days of CGM data.

Safety Considerations Specific to Children Under 12

Hypoglycemia Risk

Insulin degludec's flat pharmacodynamic profile reduces peak-related hypoglycemia, but young children are still at risk from delayed meals, unplanned exercise, and illness-related appetite loss. The SWITCH 2 pediatric data showed a 36% reduction in nocturnal hypoglycemia vs. Glargine U100 [4], but the absolute rate remained 1.4 events per patient-year in the degludec arm. That is not negligible.

Dose reductions of 20% are appropriate during illness with reduced oral intake, during periods of sustained high physical activity (summer sports camps, for example), and immediately after any severe hypoglycemia episode.

Lipohypertrophy and Injection Site Management

Consistent injection site rotation is harder to achieve in children, and lipohypertrophy at preferred sites causes erratic insulin absorption. The CDC estimates that up to 40% of insulin-dependent children develop lipohypertrophy by age 10 [8]. Rotating through abdomen, thigh, and upper arm sites on a weekly schedule reduces this risk. Sites with visible or palpable lipohypertrophy should not be used until they resolve (typically 4 to 6 months after site resting).

Storage and Handling

In-use Tresiba pens can be stored at room temperature (below 86°F / 30°C) for up to 56 days. Unopened pens require refrigeration at 36 to 46°F (2 to 8°C) [1]. School nurses managing in-school doses should keep the in-use pen at room temperature in a locked cabinet, not in a refrigerator, as cold insulin increases injection discomfort and may alter subcutaneous distribution.

Communication Between Pediatric and Adult Teams

A warm hand-off, meaning direct clinician-to-clinician communication, outperforms a records-only transfer. A 2019 systematic review in Pediatric Diabetes (14 studies, N=4,312 adolescents with type 1 diabetes) found that programs using direct provider communication at transition reduced post-transfer HbA1c deterioration by 0.3% compared with records-only transfer models (P<0.05) [9].

The ISPAD consensus guidelines recommend a minimum 6-month overlap period, during which both the pediatric and adult teams are accessible to the patient, before the pediatric team closes the file [7].

Specific to degludec: the adult provider should receive documentation of the reason degludec was chosen over glargine or detemir (for example, nocturnal hypoglycemia history, injection timing challenges, or prior loss of control with glargine U100), so they do not switch the insulin on formulary grounds without reviewing that history.